Millions of Americans take aspirin or other drugs every day to reduce their risk of heart attacks or other problems caused by blood clots.
[More]
A clot-busting therapy may benefit some heart attack patients who cannot have immediate angioplasty, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
[More]
The experimental anti-clotting drug cangrelor solidly outperformed commonly used clopidogrel in a large global trial of patients who underwent coronary stent procedures, according to data from the phase III CHAMPION PHOENIX study presented today at the American College of Cardiology's 62nd Annual Scientific Session.
[More]
A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures.
[More]
Tranexamic acid balances the increased bleeding risk associated with recent clopidogrel use in patients undergoing on-pump coronary artery bypass grafting, shows a randomized trial.
[More]
Publication of the WOEST trial results reaffirm the study’s major finding that antiplatelet therapy with clopidogrel alone is preferable to the use of both aspirin and clopidogrel in patients undergoing percutaneous coronary intervention who are receiving oral anticoagulant therapy.
[More]
Among patients scheduled for a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), pretreatment with the antiplatelet agent clopidogrel was not associated with a lower risk of overall mortality but was associated with a significantly lower risk of major coronary events, according to a review and meta-analysis of previous studies published in the December 19 issue of JAMA.
[More]
If narrowed or blocked coronary vessels have to be widened or opened, a vascular support (stent) is usually inserted. Drug-coated stents are preferred for patients at high risk of renewed narrowing of vessels (restenosis). However, the use of antibody-coated stents has been increasing in recent years. Current studies provide indications that these new antibody-coated stents more frequently lead to myocardial infarction and make re-operation necessary.
[More]
The platelet function substudy of the TRILOGY-ACS trial shows that there is no significant difference between prasugrel and clopidogrel in cardiovascular mortality, myocardial infarction, or stroke outcomes.
[More]
Cardiology researchers at the Intermountain Medical Center Heart Institute have found that approximately 75 percent of patients taking two common blood-thinning drugs may be receiving the wrong dosage levels, according to a new study.
[More]
The cause of heart attacks or strokes among some patients treated with anti-platelet drugs may be different than for patients who have undergone surgical procedures to restore blood flow, according to researchers at Duke Medicine.
[More]
An international, clinical research trial has shown that patients with diabetes whose multi-vessel coronary artery disease is treated with bypass surgery live longer and are less likely to suffer severe complications like heart attacks than those who undergo angioplasty.
[More]
Adults with diabetes and multi-vessel coronary heart disease who underwent cardiac bypass surgery had better overall heart-related outcomes than those who underwent an artery-opening procedure to improve blood flow to the heart muscle, according to the results from an international study. The research was supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.
[More]
A clinical trial indicates that using an investigational medical device to close a PFO, or "hole in the heart," may be superior to medical management alone in the prevention of a repeated stroke.
[More]
A study has found that the anti-clotting medication prasugrel reduced cardiovascular events among patients who present with an acute coronary syndrome and are managed medically after an angiogram is performed to determine coronary anatomy.
[More]
Reducing patients’ copayments for statins and clopidogrel could increase their adherence without adding financial burden to the healthcare system, researchers say.
[More]
Reducing patients’ copayments for statins and clopidogrel could increase their adherence without adding financial burden to the healthcare system, researchers say.
[More]
Older adults who have had a heart attack don't tend to adhere to their prescribed drugs according to a new study of Medicare beneficiaries by the University of Maryland School of Pharmacy.
[More]
The mortality reduction with ticagrelor versus clopidogrel is due to fewer deaths from cardiovascular, bleeding, and infection complications, say researchers.
[More]
Dual antiplatelet therapy with clopidogrel and an oral anticoagulant reduces bleeding and mortality more effectively than triple therapy including aspirin, researchers say.
[More]